Abstract:Yaling Lou, 1 Xuting Xu, 2 Ronghua Wang, 1 Danfeng Yao 3 1 Department of Clinical Pharmacy, Huzhou Central Hospital (The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University), Huzhou, People's Republic of China; 2 Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital (The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University), Huzhou, People's Republic of China; 3 Department of Pharmacy, Huzhou Maternity & Child Health Care Hospital, Huzhou, People's Republic of China Correspondence: Danfeng Yao, Department of Pharmacy, Huzhou Maternity & Child Health Care Hospital, No. 2, East Street, Wuxing District, Huzhou, 313000, People's Republic of China, Email Background: The mechanism of Chemotherapy-induced neuropathic pain (NP) remains obscure. This study was aimed to uncover the key genes as well as protein networks that contribute to Oxaliplatin-induced NP. Material/Methods: Oxaliplatin frequently results in a type of Chemotherapy-induced NP that is marked by heightened sensitivity to mechanical and cold stimuli, which can lead to intolerance and discontinuation of medication. We investigated whether these different etiologies lead to similar pathological outcomes by targeting shared genetic targets or signaling pathways. Gene expression data were obtained from the Gene Expression Comprehensive Database (GEO) for GSE38038 (representing differential expression in the spinal nerve ligation model rats) and GSE126773 (representing differential expression among the Oxaliplatin-induced NP model rats). Differential gene expression analysis was performed using GEO2R. Results: Protein-protein interaction (PPI) analysis identified 260 co-differentially expressed genes (co-DEGs). Subsequently, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed three shared pathways involved in both models: Kaposi sarcoma-associated herpesvirus (KSHV) infection, Epstein-Barr virus (EBV) infection, and AGE-RAGE signaling pathway in diabetic complications. Further bioinformatics analysis highlighted eight significantly up-regulated genes in the NP group: Mapk14, Icam1, Cd44, IL6, Cxcr4, Stat1, Casp3 and Fgf2. Our results suggest that immune dysfunction, inflammation-related factors or regulating inflammation factors may also be related to Oxaliplatin-induced NP. Additionally, we analyzed a dataset (GSE145222) involving chronic compression of DRGs (CCD) and control groups. CCD model is a classic model for studying NP. We assessed these hub genes' expression levels. In contrast with the control groups, the hub genes were up-regulated in CCD groups, the difference was statistically significant, except Stat1. Conclusion: Our research significantly contributes to elucidating the mechanisms underlying the occurrence as well as the progression of Oxaliplatin-induced NP. We have identified crucial genes and signaling pathways associated with this condition. Keywords: neuropathic pain, oxaliplatin, spinal dorsal horn, bioinformatics, differentially expressed genes, hub genes Chemotherapy-induced neuropathic pain (CINP) is a progressive, persistent, and challenging disease characterized by pain, numbness, tingling sensation, and sensitivity to cold. It affects about 50–90% of individuals undergoing chemotherapy treatment. 1 CIPN is mainly induced by first-line chemotherapy drugs such as oxaliplatin, paclitaxel, and vinblastine. With the accumulation of chemotherapy drug toxicity, peripheral neuropathological symptoms become increasingly severe, compelling patients to reduce the chemotherapy drug dosages, shorten the chemotherapy cycle, or even discontinue medication, ultimately impacting patient survival rates. Chemotherapy-induced neuropathic pain (CINP) remains a therapeutic challenge with no effective drugs and treatments currently available. Oxaliplatin is a widely used chemotherapy-drug for the treatment of colorectal and advanced ovarian cancer. 2 However, one of the major side effects associated with oxaliplatin treatment is the development of neuropathic pain (NP). This condition is characterized by severe and painful peripheral neuropathy, which can often lead to dose reduction or early discontinuation of chemotherapy. 3,4 Despite its clinical significance, the exact mechanism underlying Oxaliplatin-induced neurotoxicity and the subsequent development of NP remains unclear. Inflammation of the dorsal root ganglions (DRGs) is the pivotal physiological basis for the occurrence of NP. During the process of pain generation, the DGRs serve as the primary neuron of pain input in the pain mechanism. So the DGRs are considered to be key participants within the pathogenesis that lead to NP.<s -Abstract Truncated-

Emodin suppresses oxaliplatin‐induced neuropathic pain by inhibiting COX2/NF‐κB mediated spinal inflammation

Curcumin relieves oxaliplatin‐induced neuropathic pain via reducing inflammation and activating antioxidant response

2-Bromopalmitate decreases spinal inflammation and attenuates oxaliplatin-induced neuropathic pain via reducing Drp1-mediated mitochondrial dysfunction

Huangqi Guizhi Wuwu Decoction Alleviates Oxaliplatin-Induced Peripheral Neuropathy Via the Gut-Peripheral Nerve Axis.

Emodin alleviates chronic constriction injury-induced neuropathic pain and inflammation via modulating PPAR-gamma pathway

Identification of Key Genes and Pathways in Oxaliplatin-Induced Neuropathic Pain Through Bioinformatic Analysis

Emodin alleviates arthritis pain through reducing spinal inflammation and oxidative stress

Wen-Luo-Tong Prevents Glial Activation and Nociceptive Sensitization in a Rat Model of Oxaliplatin-Induced Neuropathic Pain

Tetrandrine alleviates oxaliplatin-induced mechanical allodynia via modulation of inflammation-related genes

Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia

Molecular Mechanism of Electroacupuncture Treatment on Oxaliplatin-Induced Peripheral Neurotoxicity in Rats

The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain

Involvement of the Spinal Serotonergic System in the Analgesic Effect of [6]-Shogaol in Oxaliplatin-Induced Neuropathic Pain in Mice

Puerarin alleviates oxaliplatin-induced neuropathic pain by promoting Nrf2/GPX4-mediated antioxidative response

Proteomic and metabolomic approaches elucidate the molecular mechanism of emodin against neuropathic pain through modulating the gamma‐aminobutyric acid (GABA)‐ergic pathway and PI3K/AKT/NF‐κB pathway

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Huangqi Guizhi Wuwu Decoction Can Prevent and Treat Oxaliplatin Induced Neuropathic Pain by TNFα/IL-1β/IL-6/MAPK/NF-kB Pathway

Emodin protects against apoptosis and inflammation by regulating reactive oxygen species-mediated NF-κB signaling in interleukin‐1β-stimulated human nucleus pulposus cells

Nrf2 Inhibits Oxaliplatin-Induced Peripheral Neuropathy Via Protection of Mitochondrial Function.

Red Ginger Extract Prevents the Development of Oxaliplatin-Induced Neuropathic Pain by Inhibiting the Spinal Noradrenergic System in Mice

αO-Conotoxin GeXIVA[1,2] Reduced Neuropathic Pain and Changed Gene Expression in Chronic Oxaliplatin-Induced Neuropathy Mice Model